Clinical Trial Detail

NCT ID NCT02868632
Title Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors New York University School of Medicine
Indications

pancreatic adenocarcinoma

Therapies

Tremelimumab

Durvalumab + Tremelimumab

Durvalumab

Age Groups: adult senior

No variant requirements are available.